INT262274

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.27
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 8
Total Number 8
Disease Relevance 1.62
Pain Relevance 0.22

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (UGCG) transferase activity, transferring glycosyl groups (UGCG) Golgi apparatus (UGCG)
Anatomy Link Frequency
puncture 1
UGCG (Homo sapiens)
Pain Link Frequency Relevance Heat
cva 194 70.48 Quite High
anesthesia 6 67.52 Quite High
antagonist 17 50.00 Quite Low
b2 receptor 7 50.00 Quite Low
Versed 6 44.28 Quite Low
drug abuse 5 11.20 Low Low
alcohol 7 10.64 Low Low
Inflammation 56 5.00 Very Low Very Low Very Low
Electroencephalography 30 5.00 Very Low Very Low Very Low
cytokine 12 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Lumbar Puncture Related Headaches 10 99.90 Very High Very High Very High
Hematoma 35 99.28 Very High Very High Very High
Infection 31 97.20 Very High Very High Very High
Coma 40 93.16 High High
Hemorrhage 15 88.56 High High
Injury 33 83.20 Quite High
Sleep Disorders 42 81.44 Quite High
Malignant Neoplastic Disease 1 72.72 Quite High
Middle Cerebral Artery Infarction 1 71.92 Quite High
Cv General 4 Under Development 104 70.48 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Adjusting for baseline GCS score the difference in the means (?)
Gene_expression (Adjusting) of GCS
1) Confidence 0.27 Published 2009 Journal Trials Section Body Doc Link PMC2794266 Disease Relevance 0.18 Pain Relevance 0
Thus, taliglucerase does not require exposure of mannose residues in vitro, which is a requirement for the production of other recombinant GCs.53 Nevertheless, higher number of mannose residues may result in increased immunogenicity due to the presentation of nonmammalian glycans.54 However, there have been no clinical adverse effects, nor increased frequency of neutralizing antibodies associated with taliglucerase during safety and pharmacokinetics studies.54 Recently, there has been serious problems in the manufacturing and processing of imiglucerase, and availability of alternative therapeutics has become more pressing than ever.
Gene_expression (production) of GCs
2) Confidence 0.11 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2909498 Disease Relevance 0 Pain Relevance 0
Patients with a GCS <13 had significantly higher APACHE II scores, baseline SOFA scores and higher baseline S100B values than those with a GCS ?
Gene_expression (<13) of GCS
3) Confidence 0.09 Published 2010 Journal Crit Care Section Body Doc Link PMC2887172 Disease Relevance 0 Pain Relevance 0
S100B levels progressively decreased during DrotAA infusion in patients with a GCS <13 only (0.96 ± 0.22 ?
Gene_expression (<13) of GCS
4) Confidence 0.09 Published 2010 Journal Crit Care Section Body Doc Link PMC2887172 Disease Relevance 0 Pain Relevance 0
Sixty-five percent of patients with a GCS <13 and 45% of patients with a GCS ?
Gene_expression (<13) of GCS
5) Confidence 0.09 Published 2010 Journal Crit Care Section Body Doc Link PMC2887172 Disease Relevance 0 Pain Relevance 0
In the group of patients with a GCS <13, those who received DrotAA tended to have higher baseline S100B levels than their untreated counterparts (1.21 ± 0.22 vs 0.95 ± 0.12 ?
Gene_expression (<13) of GCS
6) Confidence 0.09 Published 2010 Journal Crit Care Section Body Doc Link PMC2887172 Disease Relevance 0 Pain Relevance 0
A lumbar puncture was performed in all patients with a GCS ?
Gene_expression (performed) of GCS in puncture associated with lumbar puncture related headaches
7) Confidence 0.09 Published 2010 Journal Crit Care Section Body Doc Link PMC2887172 Disease Relevance 0.41 Pain Relevance 0
Finally, a multi-center randomized control trial examined the utility of sterotactic urokinase infusion when administered within 72 hours to patients with GCS score ?
Gene_expression (score) of GCS
8) Confidence 0.05 Published 2008 Journal Crit Care Section Body Doc Link PMC2646334 Disease Relevance 1.03 Pain Relevance 0.22

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox